Ramsay Lifts Underlying NPAT 22.9%, EBIT Up in Every Region

Ramsay Health Care Ltd (RMSYF) told its FY 2026 earnings call that underlying net profit after tax rose 22.9%, with every operating region delivering EBIT growth and the proposed separation of its European arm, Ramsay Sante, still on track.

Ramsay Health Care Ltd (RMSYF), the Australian hospital operator whose shares also change hands in the United States as an over-the-counter depositary receipt, used its FY 2026 earnings call to report a 22.9% increase in underlying net profit after tax. Every operating region delivered growth in earnings before interest and tax, and management said the proposed separation of its European business, Ramsay Sante, remains on track.

That is a short list of facts, but for a company of Ramsay's shape it is the list that matters most. Private hospital groups are volume-and-margin businesses with heavy fixed costs: theatres, beds, nursing rosters and imaging equipment that must be paid for whether or not a patient is on the table. When profit growth runs at more than a fifth and no region is dragging, it usually means occupancy and case mix are working in the operator's favour at the same time as pricing agreements with insurers and public payers are holding up.

Why "underlying" is the number to read carefully

Underlying NPAT strips out items management judges to be one-off or non-operational — asset sales, impairments, restructuring charges, portfolio revaluations. It is the measure most hospital groups steer on, and it is the measure Ramsay put in front of investors on the call, as reported by GuruFocus.

The caution is standard rather than specific to Ramsay: a 22.9% lift in underlying profit tells you how the operating engine ran, not what landed on the statutory bottom line after separation costs, financing charges and any writedowns. Investors reading the full accounts should reconcile the two before treating the growth rate as cash available to shareholders. A group in the middle of carving out a large European subsidiary typically carries advisory, legal and transaction expenses that sit outside the underlying figure by design.

EBIT growth in all regions is the harder achievement

The regional detail is arguably more informative than the headline. Ramsay operates across markets with structurally different payment systems — Australian private health insurance, UK independent-sector work including NHS-funded activity, and continental European tariff regimes through Ramsay Sante. Those systems do not move in step. Tariff resets, staffing shortages and inflation in consumables have hit different geographies in different years, which is why a group result can look healthy while one region quietly bleeds.

All regions posting EBIT growth removes that concern for this reporting period. It suggests the cost pressures that squeezed hospital operators through the post-pandemic period — agency nursing rates, energy, medical supplies — are being recovered through a combination of tariff and contract renegotiation, higher throughput and productivity work, rather than being absorbed in margin.

What the disclosed facts do not settle is the balance between volume and price in each market. Growth driven by more surgical cases is more durable than growth driven by a single favourable tariff uplift, because volume growth spreads fixed costs further. Anyone modelling FY 2027 should be looking for the split in the detailed regional commentary.

The Ramsay Sante separation is the valuation event

The separation of Ramsay Sante is the strategic item that could reprice the equity, and management confirming it is on track is the most consequential line on the call after the profit number.

The logic of separating a large European subsidiary from an Australian-headquartered parent is familiar. Conglomerate structures spanning multiple regulatory and reimbursement regimes tend to trade at a discount to the sum of their parts, because few investors want the whole bundle and analysts must average unlike businesses. Splitting them allows each to be valued on its own growth, capital intensity and payer risk, and allows each to raise capital against its own balance sheet.

For holders, the questions that determine whether that theory becomes cash are all structural: the form of the separation, how debt and lease obligations are allocated between the entities, what the remaining group's leverage looks like afterwards, whether any proceeds are returned or reinvested, and what stranded corporate costs stay behind. None of those were specified in the disclosures available here. "On track" is a schedule update, not a term sheet.

What the ADR line means for US holders

US investors accessing Ramsay through the RMSYF depositary receipt should understand what they own. The primary listing and primary liquidity are in Australia; the American line trades over the counter, typically in thinner volume and with wider spreads, and its price reflects the Australian dollar. A strong operating result can therefore be partly offset — or amplified — by currency movement before it reaches a US brokerage statement.

Corporate actions are the other consideration. In a separation, holders of the underlying ordinary shares and holders of a depositary receipt do not always receive identical treatment or identical timing, and any distribution of a foreign spun-off entity can carry handling and tax complications for the depositary line. That is worth checking with the broker well before any transaction completes rather than after.

The read-across for hospital operators

Broad market conditions were quiet around the report. As of the last trade on 26 August 2026, the S&P 500 tracking fund closed at $766.08, up 0.02% on the day, the Nasdaq 100 fund at $711.37, up 0.09%, and the Dow 30 fund at $534.23, down 0.19% — an unremarkable session that left company-specific news to stand on its own.

For the wider sector, Ramsay's result is a data point in favour of the argument that elective surgical demand and negotiated pricing have both recovered enough to restore operating leverage at scale private hospital groups. It is one company and one reporting period, and the regional drivers still need unpacking. But growth in every region, in a business exposed to three separate payer systems, is not easily explained by luck in any one of them.

Key facts

• Underlying NPAT growth: +22.9% in FY 2026
• Regional performance: EBIT growth reported in all regions
• Strategic status: Proposed Ramsay Sante separation on track
• Market backdrop (as of 26 Aug 2026 close): S&P 500 ETF (SPY) $766.08, +0.02%

Frequently asked questions

How much did Ramsay Health Care's profit grow in FY 2026?

Ramsay Health Care reported that underlying net profit after tax rose 22.9% in FY 2026, according to its earnings call. Underlying NPAT is a measure that excludes items management treats as one-off or non-operational, such as impairments, asset sales and restructuring costs, so it can differ from the statutory bottom-line result in the full accounts.

Did all of Ramsay's regions grow?

Yes. The company said every operating region delivered growth in EBIT — earnings before interest and tax — in FY 2026. That is notable because Ramsay operates across markets with different payment systems, including Australian private health insurance, UK independent-sector work and continental European tariff regimes, which rarely move in the same direction at the same time.

What is the Ramsay Sante separation?

Ramsay Sante is Ramsay Health Care's European business, and the company has proposed separating it from the parent group. On the FY 2026 call, management said the proposed separation remains on track. The stated schedule update does not disclose the final structure, debt allocation, timing or treatment of proceeds, all of which will determine the effect on shareholders.

Why would separating a division increase value?

Groups spanning several regulatory and reimbursement systems often trade below the sum of their parts, because investors and analysts must value unlike businesses together. Separation lets each entity be assessed on its own growth, capital needs and payer risk, and lets each fund itself. Whether value is actually released depends on debt allocation and stranded corporate costs.

What is RMSYF and how does it differ from the Australian listing?

RMSYF is the US over-the-counter depositary receipt line for Ramsay Health Care. The company's primary listing and primary liquidity are in Australia. The US line typically trades in thinner volume with wider spreads, and its price reflects the Australian dollar, so currency moves can offset or amplify operating results for American holders.

What should investors watch next?

Three things: the split between volume and price in each region's EBIT growth, since case-volume growth is more durable than a one-off tariff uplift; the reconciliation between underlying and statutory profit, which captures separation costs; and the final terms of the Ramsay Sante separation, particularly debt allocation, leverage at the remaining group and treatment of any proceeds.

Sources

• Ramsay Health Care Ltd (RMSYF) (FY 2026) Earnings Call Highlights: Strong Profit Growth and ... — GuruFocus

Photo: DΛVΞ GΛRCIΛ · Pexels Licence — source